Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.29 is 90% above its 5-year average of -2.99, near the high end of its 5-year range (-5.20–-0.29).
28.40% above its 12-month average of -0.41.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.03.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters Quote observation: 2026-10-06T11:55:27.103Z. Historical observations retain their original dates. Historical series through 2005-11-14.
EARNINGS PER SHARE (EPS)
-0.29
EARNINGS PER SHARE (EPS) AVG TTM
-0.41
EARNINGS PER SHARE (EPS) AVG 3Y
-1.95
EARNINGS PER SHARE (EPS) AVG 5Y
-2.99
EARNINGS PER SHARE (EPS) AVG 10Y
-3.85
EARNINGS PER SHARE (EPS) AVG 15Y
-13.71
EARNINGS PER SHARE (EPS) AVG 20Y
-682.40
CURRENT VS TTM AVG
+28.40%
CURRENT VS 3Y AVG
+85.15%
CURRENT VS 5Y AVG
+90.28%
CURRENT VS 10Y AVG
+92.47%
CURRENT VS 15Y AVG
+97.89%
CURRENT VS 20Y AVG
+99.96%
ABVC BioPharma, Inc.
Market Cap
$25.48M
Earnings Per Share (EPS)
-0.29
TTM Avg
-0.41
3Y Avg
-1.95
5Y Avg
-2.99
Market Cap
$24.44M
Earnings Per Share (EPS)
-4.34
TTM Avg
-3.52
3Y Avg
-3.45
5Y Avg
-7.67
Market Cap
$28.43M
Earnings Per Share (EPS)
-0.62
TTM Avg
-0.83
3Y Avg
-1.05
5Y Avg
-1.29
Market Cap
$21.90M
Earnings Per Share (EPS)
-1.66
TTM Avg
-1.66
3Y Avg
-2.82
5Y Avg
-25.82
Market Cap
$20.93M
Earnings Per Share (EPS)
-0.89
TTM Avg
-2.16
3Y Avg
-1.83
5Y Avg
-1.83
Market Cap
$30.65M
Earnings Per Share (EPS)
-3.21
TTM Avg
-2.50
3Y Avg
-4.25
5Y Avg
-9.67
Market Cap
$30.92M
Earnings Per Share (EPS)
-0.48
TTM Avg
-0.42
3Y Avg
-0.82
5Y Avg
-1.14
Market Cap
$31.36M
Earnings Per Share (EPS)
N/A
TTM Avg
-0.24
3Y Avg
-0.01
5Y Avg
0.39
Market Cap
$18.82M
Earnings Per Share (EPS)
-0.66
TTM Avg
-0.90
3Y Avg
-9.28
5Y Avg
-9.88
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| ABVC BioPharma, Inc. (ABVC) | $25.48M | -0.29 | -0.41 | -1.95 | -2.99 |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.44M | -4.34 | -3.52 | -3.45 | -7.67 |
| aTyr Pharma, Inc. (ATYR)vs › | $28.43M | -0.62 | -0.83 | -1.05 | -1.29 |
| Aytu BioPharma, Inc. (AYTU)vs › | $21.90M | -1.66 | -1.66 | -2.82 | -25.82 |
| Actuate Therapeutics Inc (ACTU)vs › | $20.93M | -0.89 | -2.16 | -1.83 | -1.83 |
| CervoMed Inc. (CRVO)vs › | $30.65M | -3.21 | -2.50 | -4.25 | -9.67 |
| Context Therapeutics Inc. (CNTX)vs › | $30.92M | -0.48 | -0.42 | -0.82 | -1.14 |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.36M | N/A | -0.24 | -0.01 | 0.39 |
| Cosmos Health Inc. (COSM)vs › | $18.82M | -0.66 | -0.90 | -9.28 | -9.88 |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.77M | -0.25 | -0.29 | -0.28 | -0.20 |
Trailing EPS (TTM)
$-0.29
Forward EPS (Est.)
$1.30
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.39 |
| 2024-12-31 | -0.42 |
| 2023-12-31 | -1.80 |
| 2022-12-31 | -5.20 |
| 2021-12-31 | -5.10 |
| 2020-12-31 | -5.00 |
| 2019-12-31 | -2.10 |
| 2018-12-31 | -4.69 |
| 2017-12-31 | -3.58 |
| 2016-09-30 | -10.21 |
| 2015-09-30 | -0.01 |
| 2014-09-30 | -126.07 |
| 2013-09-30 | -1244.19 |
| 2012-09-30 | -8102.33 |
| 2011-12-15 | -61418.00 |
| 2010-09-30 | -139823.64 |
| 2009-09-30 | -235554.18 |
| 2008-09-30 | -55043.27 |
| 2007-09-30 | -125702.70 |
| 2006-12-31 | -686.46 |
| 2005-12-31 | -720.81 |
| 2004-12-31 | 68.62 |
| 2003-12-31 | -113.23 |
| 2002-12-31 | -89.29 |
